DOI: https://doi.org/10.22141/2224-0721.15.4.2019.174816

Evaluating the informativity and specificity of diagnostic criteria for primary screening for acromegaly

O.O. Khyzhnyak, M.R. Mykytyuk, R.S. Nikolaiev, N.Ye. Barabash, K.H. Manska

Abstract


Background. The most effective method for early diagnosis of any disease, and especially such rare as acromegaly, is considered to be population screening in high­risk groups, the introduction of which in Ukraine requires the development of methodological approaches and economic substantiation. The purpose of the study: based on a comparative analysis, to determine the informativity and specificity of questions that will be included in the questionnaire of primary screening for acromegaly. Materials and methods. The survey was conducted in two groups of people: group 1 — patients with diagnosis of acromegaly verified in the neuroendocrinology center of State Institution “V. Danilevsky Institute for Endocrine Patho­logy Problems of the National Academy of Medical Sciences of Ukraine” (n = 123); group 2 (n = 550) — persons from the risk group, namely, those who came to an outpatient visit to a general practitioner, therapist, cardiologist, endocrinologist for various reasons and in the presence of somatic and/or endocrine pathology. The evaluation of the obtained data was carried out by the analysis of variance using the software complex SPSS 19.0 (IBM Corp., Armonk, NY, USA). Results. The first set of questions in the developed questionnaire is the evaluation of phenotypic characteristics, that is, the patient’s assessment of changes in his/her appearance. The second set of questions is the determination of complaints by patients that can be a sign of the presence of a pathological process in the central nervous system and pituitary gland. Based on the comparative analysis, in the final version, the questionnaire had 11 questions, which reflect the most significant signs and clinical manifestations of permanent excessive growth hormone. The questionnaire is intended for interviewing individuals at risk in order to carry out opportunistic screening for acromegaly. Conclusions. The proposed method for evaluating the significance of clinical signs of acromegaly allows us to determine with a high degree of pro­bability the final questions for the screening questionnaire.


Keywords


acromegaly; excessive growth hormone; scree­ning; survey; questionnaire

References


Melmed S, Bronstein MD, Chanson PA, et al. Consensus Statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol 2018;14(9):552-561. doi: 10.1038/s41574-018-0058-5.

Horvath E, Kovacs K. Pathology of acromegaly. Neuroendocrinology. 2006;83(3-4):161-165. DOI: 10.1159/000095524.

Kannan S, Kennedy L. Diagnosis of acromegaly: state of the art. Expert Opin Med Diagn. 2013 Sep;7(5):443-53. doi: 10.1517/17530059.2013.820181.

Daly AF, Tichomirowa MA, Beckers A. The epidemiology and genetics of pituitary adenomas. Best Pract Res Clin Endocrinol Metab. 2009 Oct;23(5):543-54. doi: 10.1016/j.beem.2009.05.008.

Nilsson B, Gustavasson-Kadaka E, Bengtsson BA, Jonsson B. Pituitary adenomas in Sweden between 1958 and 1991: incidence, survival, and mortality. J Clin Endocrinol Metab. 2000 Apr;85(4):1420-5.

Daly AF, Burlacu MC, Livadariu E, Beckers A. The epidemiology and management of pituitary incidentalomas. Horm Res. 2007;68 Suppl 5:195-8. doi: 10.1159/000110624.

Mercieca C, Gruppetta M, Vassallo J. Epidemiology, treatment trends and outcomes of acromegaly. Eur J Intern Med. 2012 Dec;23(8):e206-7. doi: 10.1016/j.ejim.2012.07.010.

Lavrentaki A, Paluzzi A, Wass JA, et al. Epidemiology of acromegaly: review of population studies. Pituitary. 2017 Feb;20(1):4-9. doi: 10.1007/s11102-016-0754-x.

Bernabeu I, Aller J, Álvarez-Escolá C, et al. Criteria for diagnosis and postoperative control of acromegaly, and screening and management of its comorbidities: Expert consensus. Endocrinol Diabetes Nutr. 2018;65(5):297-305. doi: 10.1016/j.endinu.2018.01.008.

Petrossians P, Tichomirowa MA, Stevenaert A, et al. The Liege Acromegaly Survey (LAS): a new software tool for the study of acromegaly. Ann Endocrinol (Paris). 2012;73(3):190-201. doi: 10.1016/j.ando.2012.05.001.

Bolanowski M, Zatonska K, Kaluzny M, et al. A follow-up of 130 patients with acromegaly in a single centre. Neuro Endocrinol. Lett. 2006;27(6):828-832.

Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury. Clin Endocrinol (Oxf). 2010 Mar;72(3):377-82. doi: 10.1111/j.1365-2265.2009.03667.x.

Molitvoslovova N, Przhiyalkovskaya E, Rozhinskaya L, Melnichenko G. Russian register of patients with hypothalamo-hypophyseal disorders: update to May 2010. In: Abstract book of 14th Congress of ENEA. Liege. 2010;58:119.

Sesmilo G, Webb SM. Twelve years of the Spanish acromegaly registry: a historical view of acromegaly management in Spain. Endocrinol Nutr. 2010 Feb;57(2):39-42. doi: 10.1016/j.endonu.2010.01.003.

Vandeva S, Andreeva M, Orbetsova M, et al. Acromegaly in Bulgaria – Epidemiological characteristics of acromegaly in the Bulgarian population. Endocrinologia Jrnl. 2010;(3):142-150.

Khyzhnyak O, Nikolaiev R, Guk M, Nikolaiev R, Gogitidze T. Clinical and hormonal features of acromegaly in patients from a Ukrainian neuroendocrinology centre. Problemi endokrinnoi patologii. 2019;68(2):110-130. doi: org/10.21856/j-PEP.2019.2.17.

Mykytiuk MR, Khyzhnyak OO. Analysis of national registries of patients with acromegaly of foreign countries and own observations. Endokrynologiya. 2010;15(1):107-114. (in Ukrainian).

Knutzen R, Ezzat S. The cost of medical care for the acromegalic patient. Neuroendocrinology. 2006;83(3-4):139-44. doi: 10.1159/000095521.

Daly AF, Cogne M, Jaffrain-Rea MX, et al. The epidemiology of pituitary tumors: results of an international collaborative study. In: The Endocrine Society Annual Meeting, Toronto Canada, June 2-5, 2007.

Khyzhnyak O, Velykykh N, Levchenko T, et al. Clinical observation of combined pathology – acromegaly and fibrous osteodysplasia (McCune-Albright syndrome). Problemi Endokrynnoi Patologii. 2008;4:56-62. (in Russian).

Cochrane AL, Holland WW. Validation of screening procedures. British Medical Bulletin. 1971;27(1):3-8.

Fletcher RH, Fletcher SW. Clinical Epidemiology: the essentials. Lippincott Williams & Wilkins, 2005. 252 p.

Bolanowski M, Zatonska K, Kaluzny M, et al. A follow-up of 130 patients with acromegaly in a single centre. Neuro Endocrinol. Lett. 2006;27(6):828-32.

Levy MJ, Matharu M, Goadsby PJ. Chronic headache and pituitary tumors. Curr Pain Headache Rep. 2008;12(1):74-8.

Lesén E, Granfeldt D, Houchard A, et al. Comorbidities, treatment patterns and cost-of-illness of acromegaly in Sweden: a register-linkage population-based study. Eur J Endocrinol. 2017;176(2):203-212. doi: 10.1530/EJE-16-0623.






Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© "Publishing House "Zaslavsky", 1997-2019

 

   Seo анализ сайта